In fact, the reliance of AR on microtubules is attributed to the success of microtubule targeting agent docetaxel in PCa, which is the first-line treatment and standard-of-care for metastatic CRPC [39, 40]. The gene discussed is AR; the disease is posterior cortical atrophy.